hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced an unaudited trading update for the year ended 31 December 2023.
Highlights
• | Full year revenue of £56.0 million, an increase of 15.5% (2022: £48.5 million) |
• | EBITDA margins of c.22% (2022: 18.7%) |
• | Cash of £37.0 million as at 31 December 2023 (31 December 2022: £28.4m) |
• | Weighted contracted orderbook of £80 million as at 31 December 2023 (31 December 2022: £76 million) |
• | 90% of 2024 revenue guidance already contracted and good visibility into 2025 |
• | Revenue guidance of £62 million for 2024 |
• | Move to new state-of-the-art facility in Canary Wharf on schedule to complete in H1 2024 |
• | Commencement of annual dividend payment in 2024 |
• | New medium-term target of growing Group revenue to £100m by 2028 |